Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™
Abstract
The management of HD continues to evolve, and the NCCN guidelines have undergone major changes since their inception. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects. © Journal of the National Comprehensive Cancer Network.
Publication Title
JNCCN Journal of the National Comprehensive Cancer Network
Recommended Citation
Hoppe, R., Advani, R., Bierman, P., Bloomfield, C., Buadi, F., Djulgegovic, B., Forero, A., Gordon, L., Hernandez-Ilizaliturri, F., Kaminski, M., Love, G., Maloney, D., Mauch, P., Moore, J., Schilder, R., Weiss, L., Winter, J., Yahalom, J., & Zelenetz, A. (2006). Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4 (3), 210-230. https://doi.org/10.6004/jnccn.2006.0021
